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 BRIEF COMMUNICATION 
osteosarcoma U2OS cells ( 12 ) to undergo 
apoptosis [assessed by scoring the percent-
age of cells displaying pycnotic nuclei ( 9 )] 
decreased as a function of increasing pep-
tide preincubation time in serum-contain-
ing medium, suggesting that this peptide is 
sensitive to degradation by serum proteases 
( Figure 1, A ). This sensitivity to degrada-
tion is likely to adversely affect the antitu-
mor activity of the peptide in vivo. One 
way to render a peptide more resistant to 
proteolytic degradation is to convert its 
amino acids from the natural  l -form to the 
protease-resistant  d -form. To best mimic 
the structure of the natural peptide, the 
sequence of the  d -peptide is generally 
inverted, generating the so-called retro-
inverso form ( 13 , 14 ). After preincubation 
in serum-containing medium for up to 2 
days, the retro-inverso form of TAT-
RasGAP 317 – 326 (RI·TAT-RasGAP 317 – 326 ) 
showed almost no decrease in its ability to 
sensitize U2OS cells to cisplatin-induced 
apoptosis ( Figure 1, A ). This ﬁ nding suggests 
that RI·TAT-RasGAP 317 – 326 is a more stable 
compound than L·TAT-RasGAP 317 – 326 . 
Dose – response analyses indicated that 
RI·TAT-RasGAP 317 – 326 was more effective 
than L·TAT-RasGAP 317 – 326 in sensitizing 
U2OS cells to the apoptosis-inducing 
action of cisplatin ( Figure 1, B and C ), a 
likely reﬂ ection of its higher stability com-
pared with L·TAT-RasGAP 317 – 326 . 
 Another parameter that can affect the 
efﬁ cacy of an anticancer compound in vivo 
is its rate of clearance from the circulation. 
We used liquid chromatography coupled 
with mass spectrometry to examine the 
persistence of RI·TAT-RasGAP 317 – 326 in 
blood samples taken at various times from 
 Chemotherapeutic drugs kill tumor cells by 
activating apoptosis. If this activation is com-
promised (eg, through additional gene muta-
tions), a tumor may develop resistance to the 
anticancer drugs ( 1 , 2 ). Consequently, strate-
gies to restore tumor sensitivity to apoptosis 
are promising approaches for treating can-
cer. Much is now known about the mode of 
action of proteins that regulate cell death in 
cancer cells. This knowledge has led to the 
design of peptides that, in vitro, can perturb 
the resistance of cancer cells to anticancer 
agents ( 3 , 4 ). However, few studies have 
examined the efﬁ cacy of those peptides as 
anticancer compounds in vivo ( 3 ). 
 We have previously reported that frag-
ment N2, a caspase-generated polypeptide 
from RasGAP, a regulator of Ras- and 
Rho-dependent pathways, strongly sensi-
tizes tumor cells, but not normal cells, to 
genotoxin-induced apoptosis ( 5 , 6 ). The 
tumor sensitization property of the N2 frag-
ment is contained within a 10 – amino acid 
sequence (amino acids 317 – 326) ( 7 ). A syn-
thetic peptide (called TAT-RasGAP 317 – 326 ) 
corresponding to this sequence fused to a 
cell-permeable peptide derived from the 
human immunodeﬁ ciency virus TAT pro-
tein was found to efﬁ ciently increase the 
extent of apoptosis induced by a variety of 
genotoxins ( 7 ) and other anticancer treat-
ments ( 8 ) in several tumor cell lines. Although 
it is now known that tumor cells must be 
able to activate the p53 and p53-upregulated 
modulator of apoptosis (PUMA) pathway 
for them to undergo TAT-RasGAP 317 – 326 peptide – 
mediated sensitization to genotoxin-
induced apoptosis ( 9 ), the molecular 
mechanisms underlying the apoptosis sen-
sitization property of TAT-RasGAP 317 – 326 
remain to be characterized in detail. Here, 
we assessed the ability of TAT-RasGAP 317 – 326 
to increase the efﬁ cacy of genotoxins in an 
in vivo context. 
 We ﬁ rst examined the functional stabil-
ity of the peptide in biological ﬂ uids because 
it has been shown that peptides that are 
susceptible to proteolytic degradation can 
rapidly lose their function ( 10 , 11 ). Indeed, 
the ability of the natural  l -form of TAT-
RasGAP 317 – 326 (L·TAT-RasGAP 317 – 326 ) to sen-
sitize cisplatin-treated human p53-positive 
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a 7-week-old female NMRI Nu/Nu (nude) 
mouse (Janvier, Le Genest-St-Isle, France) 
that received a single intraperitoneal injec-
tion with the peptide at 3.3 mg/kg body 
weight. All experiments involving mice 
were approved by the State of Vaud 
Veterinary Ofﬁ ce (Lausanne, Switzerland). 
RI·TAT-RasGAP 317 – 326 was detectable in 
the circulation as early as 15 minutes after 
injection and for at least 90 minutes after 
injection; peak concentrations were 
observed 1 hour after the injection of the 
peptide (Supplementary Figure 1, A and B, 
available online). By contrast, we could not 
detect the peptide in blood samples 
obtained from two mice that were similarly 
injected with L·TAT-RasGAP 317 – 326 (data 
not shown), consistent with the notion that 
the  l -peptide is less stable, or more rapidly 
cleared, than the retro-inverso form. The 
observation that RI·TAT-RasGAP 317 – 326 
could be detected in the circulation for 
relatively long periods of time suggested 
that it might be able to reach distant tis-
sues, including tumors, after it is injected 
into mice. To test this possibility, a nude 
mouse bearing a visible tumor derived from 
subcutaneous injection of human colon 
cancer HCT116 cells was injected intrap-
eritoneally with RI·TAT-RasGAP 317 – 326 
(4.8 mg/kg body weight). The mouse was 
killed approximately 1 hour after peptide 
injection, and its liver, lungs, brain, and the 
tumor were removed and processed for 
peptide detection by mass spectrometry. 
RI·TAT-RasGAP 317 – 326 was detectable in 
the liver and lungs of this mouse but was 
not found in the brain (Supplemental 
Figure 1, C, available online), suggesting 
that it may not cross the blood – brain bar-
rier. Importantly, RI·TAT-RasGAP 317 – 326 
was also detected in the subcutaneous 
tumor. 
 We next evaluated the toxicity of 
RI·TAT-RasGAP 317 – 326 in nude mice that 
were injected intraperitoneally twice per week 
for 4 weeks with RI·TAT-RasGAP 317 – 326 
or RI·TAT (a control peptide consisting 
of the retro-inverso form of the TAT pep-
tide) (dose range  =  0.8 – 7.2 mg peptide/kg 
body weight; n  =  3 – 4 mice per group). 
Intraperitoneal injection of RI·TAT-
RasGAP 317 – 326 at a dose of 4.8 mg/kg of 
mouse body weight was lethal (three of the 
three injected mice died, all within 45 – 60 
minutes after the ﬁ rst injection), whereas a 
dose of 2.4 mg/kg body weight was not, 
even after repeated injections (three of the 
three injected mice were alive after the 
eighth injection) (Supplementary Table 1, 
available online). These results indicate 
that the dose of RI·TAT-RasGAP 317 – 326 that 
is lethal to 50% of mice (ie, the LD 50 ) is 
between  2.4  and 4.8 mg/kg body weight. 
The lethality induced by high doses of 
RI·TAT-RasGAP 317 – 326 did not seem to be 
due to the presence of the cell-permeable 
TAT peptide because none of the three 
mice injected intraperitoneally with 
RI·TAT at a dose of 4.8 mg/kg body weight 
died. Necropsy revealed that the cause of 
death in mice injected with lethal doses of 
RI·TAT-RasGAP 317 – 326 appeared to be mas-
sive hemorrhages in the lungs and kidneys 
(Supplementary Figure 1, D, available 
online). No damage to the liver, pancreas, 
or spleen was observed (data not shown). 
 We next conducted two types of in vivo 
experiments to examine the effect of 
RI·TAT-RasGAP 317 – 326 on the efﬁ cacy of 
cisplatin against tumors, in particular under 
conditions in which the doses of cisplatin 
had poor or marginal effects. In the 
ﬁ rst experiment, 7-week-old female nude 
mice were injected intraperitoneally with 
1.5 × 10 6 HCT116 cells. Beginning the 
next day, the mice were injected intraperi-
toneally twice per week for 4 weeks with 
phosphate-buffered saline (PBS), cisplatin 
(1 mg/kg body weight; catalog no. P4394, 
Sigma-Aldrich, St Louis, MO), RI·TAT-
RasGAP 317 – 326 (2.4 mg/kg body weight), or 
cisplatin plus RI·TAT-RasGAP 317 – 326 
(n  =  15 – 24 mice per group). At the end of 
the treatment period, the mice were killed 
by cervical dislocation, and their tumors 
were removed, weighed (when possible), 
and scored empirically as follows: tumors 
weighing more than 1 mg (score 5), tumors 
weighing more than 0.5 mg up to 1 mg 
(score 4), tumors weighing more than 0.1 
mg up to 0.5 mg (score 3), vascularized 
tumors grouped in clumps but too small to 
be weighed (score 2), or nonvascularized 
dispersed tumors too small to be weighed 
(score 1). Mice treated with RI·TAT-
RasGAP 317 – 326 plus cisplatin developed sta-
tistically signiﬁ cantly fewer tumors with 
higher scores than mice treated with cispla-
tin alone ( P  =  .032, two-sample location 
exact two-sided Wilcoxon test; all statistical 
analyses were performed using SAS/STAT 
software v9.1.3, SAS Institute, Inc. (Cary, 
NC) ( Figure 2, A ). This ﬁ nding indicates 
that cisplatin in combination with the pep-
tide hampers tumor growth better than 
cisplatin alone. 
 In the second type of experiment, 
HCT116 cells were injected subcutane-
ously into the left and right upper ﬂ anks of 
7-week-old female nude mice (2.5 × 10 5 
cells injected per ﬂ ank). One week later, 
when visible tumors had developed, the 
mice were injected intraperitoneally once 
per day for 1 week with PBS, RI·TAT-
RasGAP 317 – 326 (1.65 mg/kg body weight), or 
cisplatin (0.5 mg/kg body weight) or doxo-
rubicin (0.25 mg/kg body weight; catalog 
no. D1515, Sigma-Aldrich), alone or in 
combination with RI·TAT-RasGAP 317 – 326 
(n  =  4 – 7 mice per group). We tested doxo-
rubicin because it is structurally different 
from cisplatin and has a different mode of 
action ( 15 ). The orthogonal dimensions of 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Peptides that interfere with the natural 
resistance of cancer cells to genotoxin-
induced apoptosis in vitro, such as 
TAT-RasGAP 
317 – 326
 , a cell-permeable 
RasGAP-derived peptide, may improve the 
efficacy of anticancer regimens in vivo. 
 Study design 
 Examination of the in vitro and in vivo sta-
bility of a protease-resistant  d -form of the 
peptide, RI·TAT-RasGAP 
317 – 326
 , and its effect 
on tumor growth in nude mice bearing sub-
cutaneous human colon cancer HCT116 
xenograft tumors. 
 Contribution 
 RI·TAT-RasGAP 
317 – 326
 was stable in biologi-
cal fluids, and after injection into mice, it 
persisted in the bloodstream for more than 
1 hour, reached distant tissues and subcu-
taneous tumors, was effective at doses at 
least 150-fold below the dose lethal to 50% 
of mice, and improved the efficacy of 
genotoxins. 
 Implications 
 RI·TAT-RasGAP 
317 – 326
 may be useful for 
improving the efficacy of chemotherapy in 
patients. 
 Limitations 
 Tumors in nude (ie, immunocompromised) 
mice may not behave the same as synge-
neic tumors in immunocompetent mice. 
 From the Editors 
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 Figure 1 .  Effects of the L and the RI forms of TAT-
RasGAP 
317 – 326
 on cisplatin-induced apoptosis in 
U2OS cells. Sequences of the peptide used in 
the ﬁ gure: RI·TAT-RasGAP 
317 – 326
 , DTRLNTVWM-
WGGRRRQRRKKRG ( d -amino acid); L·TAT-
RasGAP 
317 – 326
 , GRKKRRQRRRGGWMWVTNLRTD 
( l -amino acid); RI·TAT, RRRQRRKKRG ( d -amino 
acid); and L·TAT, GRKKRRQRRR ( l -amino acid). 
Apoptosis was assessed by counting the cells that 
displayed a pycnotic nucleus. The results presented 
in each panel correspond to the mean percentage of 
apoptotic cells for three independent experiments; 
 error bars correspond to 95% conﬁ dence intervals. 
 A ) Peptide functional stability assay. U2OS cells 
were incubated for 20 hours with 15  µ M cisplatin 
plus the indicated peptides, which were previously 
preincubated for the indicated times in Dulbecco ’ s 
modiﬁ ed Eagle medium containing 10% newborn 
calf serum. Apoptosis was then assessed.  B ) Tumor 
cell sensitization in response to increasing peptide 
concentrations. U2OS cells were treated for 20 
hours with increasing concentrations of the indi-
cated peptides in the absence ( left panel ) or pres-
ence ( right panel ) of 15  µ M cisplatin. Apoptosis was 
then assessed.  C ) Tumor cell sensitization induced 
by the peptides in response to increasing cisplatin 
concentrations. U2OS cells were treated for 20 
hours without (Control) or with (20  µ M ﬁ nal concen-
tration) the indicated peptides in the presence of 
increasing concentrations of cisplatin. Apoptosis 
was then assessed. The values for L·TAT and RI·TAT 
are slightly offset for better visualization. L  =  natural; 
RI  =  retro-inverso. 
the tumors were measured daily with the 
use of a caliper on isoﬂ urane-anesthetized 
mice, beginning on the ﬁ rst day of treat-
ment injection (day 0, ie, when tumors 
were just visible), for up to 13 days. Tumor 
volume was calculated as [(largest orthogo-
nal dimension) 2 × (smallest orthogonal 
dimension) × (  /6)]. When a mouse devel-
oped tumors on both ﬂ anks, the volumes of 
the two tumors were averaged to get a sin-
gle value for that mouse to allow statistical 
comparisons with mice that developed only 
one tumor. All mice in a given experiment 
were killed by cervical dislocation while 
still anesthetized when the largest tumors 
exceeded a  speciﬁ c  threshold volume (500 –
 1000 mm 3 , depending on the experiment). 
Mice treated with RI·TAT-RasGAP 317 – 326 
plus either cisplatin or doxorubicin devel-
oped statistically signiﬁ cantly smaller 
tumors than mice treated with RI·TAT-
RasGAP 317 – 326 ( P  =  .005 and  P < .001, respec-
tively) or with the respective genotoxin 
alone ( P  =  .004 and  P  =  .005, respectively; 
repeated measures analysis of variance 
[ANOVA, two-sided]) ( Figure 2, B and C ). 
Compared with PBS, RI·TAT-RasGAP 317 –
 326 by itself had no effect on tumor growth 
( P  =  .89 and  P  =  .41 for the cisplatin and 
doxorubicin experiments, respectively; 
repeated measures ANOVA [two-sided]). 
These data demonstrate that RI·TAT-
RasGAP 317 – 326 can inhibit the growth of 
already formed and detectable tumors when 
used in combination with a genotoxin (cis-
platin or doxorubicin). 
 Given our ﬁ nding that one injection 
of a lethal dose of TAT-RasGAP 317 – 326 led 
to hemorrhages in lungs and kidneys 
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 Figure 2 .  In vivo chemosensitizing efﬁ cacy of RI·TAT-
RasGAP 
317 – 326
 .  A ) Effect of RI·TAT-RasGAP 
317 – 326
 on intraperi-
toneal tumors. Nude mice (7-week-old females) were 
injected with 1.5 million HCT116 cells intraperitoneally. 
The following day and thereafter twice a week, the mice 
were injected intraperitoneally with PBS, 2.4 mg/kg of 
RI·TAT-RasGAP 
317 – 326
 , 1 mg/kg cisplatin, or a combination 
of cisplatin and RI·TAT-RasGAP 
317 – 326
 . After 28 days, the 
mice were killed and the development of the tumors 
scored (score 5, tumors weighing more than 1 mg; score 
4, tumors weighing between 0.5 and 1 mg; score 3, 
tumors weighing between 0.1 and 0.5 mg; score 2, vascu-
larized tumors grouped in clumps but too small to be 
weighed; and score 1, nonvascularized dispersed tumors 
too small to be weighed); examples of tumors with scores 
1 and 2 are shown on the right in ( A ). Mice that did not 
show any presence of tumors (ie, mice in which the 
tumors did not “take”) were excluded from the analysis 
(PBS: four mice excluded of 15 injected; RI·TAT-
RasGAP 
317 – 326
 : three mice excluded of 15 injected; cisplatin: 
one mouse excluded of 21 injected; cisplatin + RI·TAT-
RasGAP 
317 – 326
 : four mice excluded of 24 injected); the pro-
portion of excluded mice did not differ statistically 
signiﬁ cantly among the groups (Fisher exact test,  P  =  .225). 
The  dots represent individual mice. Statistical analysis for 
the difference between the cisplatin and the cisplatin + 
RI·TAT-RasGAP 
317 – 326
 groups was performed with a two-
sample location exact two-sided Wilcoxon test.  B and C ) 
Cisplatin- and doxorubicin-sensitizing effect of RI·TAT-
RasGAP 
317 – 326
 on subcutaneous tumors. Nude mice 
(7-week-old females) were injected subcutaneously with 
250  000 HCT116 cells on the left and right upper ﬂ anks. 
Seven days later, the mice that developed visible tumors 
were injected each day for 7 consecutive days (in  red in 
the ﬁ gure) with PBS (300  µ L), RI·TAT-RasGAP 
317 – 326
 (1.65 
mg/kg in 300  µ L PBS), cisplatin (0.5 mg/kg in 300  µ L PBS), 
or RI·TAT-RasGAP 
317 – 326
 plus cisplatin ( B ). In the experi-
ment described in ( C ), cisplatin was replaced with 0.25 
mg/kg doxorubicin. Tumor volume was plotted as a func-
tion of time (for mice that developed tumors on both 
ﬂ anks, the two tumor volumes were averaged). The num-
ber of mice analyzed is indicated in the ﬁ gure. Mean val-
ues are plotted, and  error bars correspond to 95% 
conﬁ dence intervals.  D ) Dose – response analysis of the in 
vivo sensitizing effect of the peptide. Nude mice were 
treated and analyzed as in ( B ) but with the conditions 
indicated in the ﬁ gure.  E ) Peptide injection frequency. 
Nude mice were injected subcutaneously with 500  000 
HCT116 cells and treated as described in ( D ), except that 
0.16 mg/kg body weight RI·TAT-RasGAP 
317 – 326
 was injected 
on the indicated days [ open diamonds ,  triangles , and 
 squares ; cisplatin was injected every day as in ( D )]. The  P 
values in ( B – E ) are from repeated measures ANOVA (two-
sided). ANOVA  =  analysis of variance; PBS  =  phosphate-
buffered saline; RI  =  retro-inverso. 
(Supplementary  Figure 1, D, available 
online ), we assessed whether the nonlethal 
dose of RI·TAT-RasGAP 317 – 326 that 
enhanced the sensitivity of tumors to cis-
platin and doxorubicin in the previous 
experiment had any effect on these organs. 
Non – tumor-bearing mice were injected 
with PBS, RI·TAT-RasGAP 317 – 326 , cispla-
tin, or RI·TAT-RasGAP 317 – 326 plus cisplatin 
as described above (n  =  2 mice per group); 
the mice were killed by cervical dislocation 
after the last injection (ie, 8 days after the 
ﬁ rst injection), and histological sections of 
their lungs and kidneys were prepared. We 
observed no damage to these organs in any 
of the mice (Supplementary Figure 1, E, 
available online). Thus, a nonlethal dose of 
RI·TAT-RasGAP 317 – 326 (1.65 mg/kg body 
weight), which was only approximately 
two- to three fold lower than the lethal 
dose ( ~ 5 mg/kg body weight), did not 
appear to cause visible alterations in the 
lungs or kidneys, even when it was admin-
istered in the presence of cisplatin. 
 To examine if RI·TAT-RasGAP 317 – 326 
doses lower than 1.65 mg/kg body weight 
could exert a genotoxin-sensitizing effect on 
tumor growth in mice, we used the experi-
mental design described above but with 
decreasing doses of injected RI·TAT-
RasGAP 317 – 326 and with a dose of cisplatin 
that is at the threshold of inducing an inhibi-
tory effect on tumor growth by itself. This 
dose of cisplatin was determined by inject-
ing mice with various doses of cisplatin only 
(range  =  0.005 – 1 mg/kg body weight) using 
the injection protocol shown in  Figure 2, B . 
The highest dose of cisplatin tested that did 
not reduce tumor growth was found to be 
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0.1 mg/kg body weight (data not shown). 
HCT116 tumor – bearing mice were treated 
with PBS or RI·TAT-RasGAP 317 – 326 (at doses 
of 0, 0.16, 0.048, or 0.160 mg/kg body 
weight) combined with cisplatin at 0.1 mg/
kg body weight (n  =  4 – 8 mice per group). 
Cisplatin alone (0.1 mg/kg body weight) had 
no effect on the growth of HCT116 tumors 
compared with PBS ( P  =  .77; repeated mea-
sures ANOVA [two-sided]) ( Figure 2, D ). 
However, cisplatin plus RI·TAT-RasGAP 317 –
 326 at 0.16 mg/kg body weight efﬁ ciently 
inhibited tumor growth compared with cis-
platin alone ( P  =  .03; repeated measures 
ANOVA [two-sided]). Importantly, 
RI·TAT-RasGAP 317 – 326 at 0.016 mg/kg body 
weight, a dose more than 150-fold lower 
than the estimated LD 50 (ie, between  2.4 and 
4.8 mg/kg body weight), also improved the 
efﬁ cacy of cisplatin to inhibit the growth of 
HCT116 tumors compared with cisplatin 
alone ( P  =  .004; repeated measures ANOVA 
[two-sided]). 
 We also examined the effect of varying 
the frequency of RI·TAT-RasGAP 317 – 326 
peptide injection on tumor growth. HCT116 
tumor – bearing mice were injected for 1 
week with RI·TAT-RasGAP 317 – 326 (0.16 mg/
kg body weight), daily, every other day, or 
every 3.5 days, in combination with a daily 
injection of cisplatin (0.1 mg/kg body 
weight) (n  =  3 – 7 mice per group). Control 
mice were injected daily with PBS or cispla-
tin alone. Tumor volumes were measured 
every 3 – 4 days. Injection of the peptide 
every other day sensitized tumor cells to 
cisplatin (every-other-day peptide injection 
+ cisplatin vs cisplatin only:  P  =  .02; repeated 
measures ANOVA [two-sided]) as efﬁ ciently 
as daily injection of the peptide (every-oth-
er-day peptide injection + cisplatin vs daily 
peptide injection + cisplatin:  P  =  .94; repeated 
measures ANOVA [two-sided]). Injection of 
the peptide every 3.5 days also sensitized the 
tumors somewhat to cisplatin (every 3.5 
days peptide injection + cisplatin vs cisplatin 
only:  P  =  .15; repeated measures ANOVA 
[two-sided]) but with reduced efﬁ ciency 
compared with daily or every-other-day 
injections of the peptide. These results indi-
cate that RI·TAT-RasGAP 317 – 326 does not 
need to be injected every day along with 
cisplatin to exert its sensitization property, 
probably because of its increased resistance 
to degradation in biological ﬂ uids. 
 A limitation of this study is that tumors 
in immunocompromised mouse models 
(eg, nude mice) may not behave as synge-
neic tumors in immunocompetent mice. 
Indeed, there is now clear evidence that the 
immune system positively modulates some 
anticancer therapies ( 16 ). For example, 
doxorubicin-induced death of colon carci-
noma cells implanted in syngeneic mice 
elicits an immune response that favors the 
elimination of the tumor cells ( 17 ). The 
efﬁ cacy of RI·TAT-RasGAP 317 – 326 against 
human tumors implanted in nude mice 
might therefore be attenuated by the lack 
of an intact immune system in nude mice. 
 The properties of RI·TAT-RasGAP 317 – 326 
described here in mouse tumor models indi-
cate that this peptide has the potential to be 
used in humans to sensitize tumor cells to 
genotoxin treatments (ie, to enhance the 
antitumor effect of genotoxins): it is stable 
in biological ﬂ uids, it persists in the blood-
stream for more than 1 hour after intraperi-
toneal injection, it reaches distant tissues 
and organs (including subcutaneous tumors), 
its efﬁ cacious doses are at least 100-fold 
below the LD 50 , and it greatly improves the 
efﬁ cacy of genotoxins. To our knowledge, 
this peptide is the only compound that has 
been shown to improve the efﬁ cacy of geno-
toxins and that behaves strictly as a chemo-
sensitizer, that is, it has no effect on tumors 
by itself ( 4 ). This compound would there-
fore have the potential to improve the efﬁ -
cacy of chemotherapeutic agents that are 
currently used in the clinic, particularly in 
situations in which doses of genotoxin have 
to be lowered to reduce side effects. 
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